Skip to main content
Clinical Trials/NCT05122598
NCT05122598
Unknown
Phase 2

Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease (AD)

Evon Medics LLC3 sites in 1 country200 target enrollmentNovember 15, 2021

Overview

Phase
Phase 2
Intervention
COT
Conditions
Mild Cognitive Impairment
Sponsor
Evon Medics LLC
Enrollment
200
Locations
3
Primary Endpoint
Logical Memory II subscale (Delayed Paragraph Recall)
Last Updated
3 years ago

Overview

Brief Summary

The purpose of this study is to determine whether daily treatment with this new treatment approach, called COT would be effective in protecting the memory and brain regions of people who are already showing signs of memory loss.

Detailed Description

Alzheimer's disease process starts in parts of the brain used for perceiving and interpreting smell many years before people begin to lose their memory and other cognitive functions. These parts of the brain are called the "olfactory regions." From these olfactory regions, Alzheimer's disease spread to involve other parts of the brain. Scientists have shown that stimulating the olfactory regions through exposure to multiple naturally occurring essential or plant oils help to reduce the brain changes of Alzheimer's disease in animals. Also, many components from these plant oils have been shown to protect nerve cells from various kinds of stress and injuries; and we say they are 'neuroprotective'. A novel home-based olfactory chemosensory stimulation program that uses a portable, programmed, device known as the Computerized Olfactory Training (COT) program, administers olfactory psychophysical tasks while patients are being stimulated repeatedly with neuroprotective olfactory stimulants, using neuroscience-guided stimulation parameters to ensure sustained activation of all primary and secondary olfactory structures.

Registry
clinicaltrials.gov
Start Date
November 15, 2021
End Date
April 30, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 55-95 years; female must be post-menopausal for ≥ 2 consecutive years
  • Probable mild AD according to the core clinical criteria outlined in the National Institute on Aging/Alzheimer's Association (NIA-AA) Guidelines
  • MMSE score between the range of 21 to 27; CDR score of 1.0 (mild AD); scores on Logical Memory II subscale (Delayed Recall) from the Wechsler Memory Scale-Revised (WMS) within the recommended education-adjusted ranges
  • Have either cerebrospinal fluid (CSF) Aβ42 levels that are consistent with Alzheimer's disease as measured via mass spectrometry by C2N, or document elevated amyloid burden consistent with Alzheimer's disease from positron emission tomography (PET) imaging
  • Screening MRI without evidence of infection, infarction, or other focal lesions of neurological disease; and no significant nasal disease.
  • All participants must have a study partner with normal cognitive function.

Exclusion Criteria

  • Any significant neurologic disease
  • Major psychiatric disorder within the past 2 years
  • Substance use disorder within the past 2 years
  • Any unstable medical condition
  • Contraindications to MRI
  • Any Alzheimer's disease modifying therapy (DMT) in the past 6 months
  • Antipsychotics, anticholinergics, anticonvulsants, and other antidepressants, benzodiazepines, or other psychotropic medications and blood thinners, except for aspirin at a prophylactic dose or less.

Arms & Interventions

Computerized Olfactory Training (COT) Device with olfactory stimulants

COT device with olfactory stimulants consists of daily 40 cycles of intervention with a combination of olfactory stimulation and training tasks, lasting \~45 minutes, delivered once daily over 6 months period by the participant or their partner/caregiver.

Intervention: COT

Sham/COT Device

This is COT device that uses compressed room air scented with phenylethylamine (rose scent) instead of olfactory stimulants and has shape pattern matching tasks instead of cognitive tasks, in order to blind users to their treatment assignment. Similar to the COT, sham COT will be used daily for 45 minutes.

Intervention: Sham

Outcomes

Primary Outcomes

Logical Memory II subscale (Delayed Paragraph Recall)

Time Frame: 9 months

Measures patient's ability to recall information after a 20 to 30 minutes delay for story b from the Wechsler Memory Scale-IV (0-25). Higher scores indicate better performance. This is use for evaluation of forgetting or memory decay.

ADCS-PACC composite score

Time Frame: 9 months

Combines tests that assess episodic memory, timed executive function and global cognition. Alzheimer's Disease Cooperative Study (ADCS) PACC (ADAS-PACC) is a composite score of: The Total Recall score from the Free and Cued Selective Reminding Test (FCSRT) (range from 0-48 points), The Delayed Recall score on the Logical Memory IIa subtest from the Wechsler Memory Scale (range from 0-25 points), the Digit Symbol Substitution Test score from the Wechsler Adult Intelligence Scale-Revised (range from 0-93 points), and the MMSE score (range from 0-30 points). Each of the component change scores is divided by the baseline sample standard deviation of that component, to form standardized z scores. These z scores are summed to form the composite. Z Scores could range from -5 to +5 with higher scores indicating less deficit and lower scores indicating greater deficit.

Olfactory Psychophysical Tasks scores

Time Frame: 9 months

Using Sniffin' sticks, defines patient's olfactory threshold (T), discrimination (D) and identification (I). Scores: Male and Female threshold score (1-16); Male and Female discrimination score (4-16); Identification score (male: 3-16; female: 4-16); TDI composite score (male: 9-44; female: 11-43). Higher score indicates better olfactory performance.

Changes in cortical thickness and grey matter volumes

Time Frame: Baseline and 9 months

Defines as MRI imaging changes of the hippocampus and entorhinal cortex

Changes in subfield segmentations of the hippocampus and entorhinal cortex

Time Frame: Baseline and 9 months

Using the Automatic Segmentation of Hippocampal subfields looking for changes in the hippocampus and entorhinal cortex

Secondary Outcomes

  • Changes in the scores of Neuropsychological Test Battery (NTB)(Baseline, 6 months and 9 months)
  • Changes in the scores of Mini Mental State Examination (MMSE)(Baseline, 6 months and 9 months)
  • Changes in the scores of CDR scale (CDR)(Baseline, 6 months and 9 months)
  • Changes in the scores of Global Deterioration Scale(GDS)(Baseline, 6 months and 9 months)
  • Changes in the scores of Activities of Daily Living (ADCS-ADL)(Baseline, 6 months and 9 months)
  • Changes in the scores of Quality of Life scale (QOL)(Baseline, 6 months and 9 months)
  • Changes in odor discrimination scores(Baseline, 9 months)
  • Changes in the grey matter volumes of other structures of the primary olfactory cortex(Baseline, 9 months)
  • Changes in the cortical thickness of other structures of the primary olfactory cortex(Baseline, 9 months)

Study Sites (3)

Loading locations...

Similar Trials